GHO Capital closes €2.5bn Fund IV, boosts healthcare AUM to €9B

GHO Capital has completed the final close of its fourth flagship vehicle, securing more than €2.5 billion to continue its strategy of backing specialised healthcare businesses. The raise, the largest in the firm's history, lifts the group’s total assets under management to approximately €9 billion, positioning GHO as Europe’s biggest healthcare‑focused private equity manager by AUM based in the region.

The new vehicle — Fund IV — is roughly 25% larger than its predecessor and reflects a broadened investor mix: GHO says it onboarded over 30 new institutional partners spanning Europe, North America, Asia Pacific and the Middle East while retaining support from long‑term backers. That geographic diversification gives the firm more dry powder and optionality to pursue cross‑border platform roll‑outs.

GHO will continue to deploy capital across a multi‑vertical healthcare mandate, concentrating on BioPharma, MedTech, Advisory & Data, Life Science Tools & Diagnostics and HealthTech. Management frames the strategy around building vertically integrated platforms that scale regionally and migrate to transatlantic market leadership, with an operational playbook engineered to speed commercialization and widen accessibility.

Activity since the previous close in 2021 underlines that approach. In 2025 GHO announced three platform investments: Avid Bioservices, a contract development and manufacturing organisation for biologics; Scientist.com, an AI‑driven R&D orchestration marketplace; and FotoFinder Systems, a specialist in dermatology imaging and diagnostics. These deals illustrate the firm’s tilt towards technical healthcare assets where operational improvements and international expansion can meaningfully boost value.

Alongside fundraising, GHO has been scaling its team to support a transatlantic footprint. Since Fund III’s close the firm has added 19 new hires, growing to just over 75 professionals who can provide on‑the‑ground support in Europe and the US. Senior bench strength was also enhanced with the appointment of a Partner in 2024 plus five integrated Operating Partners and Senior Advisors focused on value creation.

Managing Partners Mike Mortimer, Alan Mackay and Andrea Ponti framed the raise as validation of a sector‑specialist approach in an otherwise cautious capital raising environment. For limited partners, healthcare remains an attractive allocation: demographic trends, the increasing complexity of therapeutics and the digitisation of care are structural drivers that support durable deal flow and resilient returns.

From a market perspective, specialist healthcare funds continue to differentiate themselves by offering deep operational expertise and sector networks that generalist buyout firms may lack. For Europe, a transatlantic playbook matters: US markets often offer greater scale and exit optionality, while European regulatory know‑how and clinical relationships remain critical for commercialisation. GHO’s enlarged Fund IV is therefore positioned to pursue both regional consolidation and cross‑border expansion as it builds the next generation of healthcare platforms.